Encephalopathy News and Research

RSS

New research may shed light on possible treatments for prion diseases

New research by Chongsuk Ryou, researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology and molecular genetics in the UK College of Medicine, may shed light on possible treatments for prion diseases.

15 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Baby frozen to correct brain damage at birth makes full recovery

Baby Ella was born starved of oxygen but doctors cooled her body for three days to reduce brain damage. She made a complete recovery. After birth Ella was wrapped in a special blanket filled with fluid which cooled her whole body down from the normal 37°c to 33.5°c by doctors at Addenbrooke’s Hospital in Cambridge.

3 Mar 2011

New study examines boxing injuries among children and adolescents from 1990 to 2008

The risk and nature of injury in the sport of boxing has generated a great deal of controversy in the medical community, especially in relation to youth boxing. A new study, conducted by researchers in the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital, examined boxing injuries among participants 6 years of age and older from 1990 to 2008.

3 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Blood test for screening mad cow disease to come soon: Study

UK scientists have developed a new blood test that can diagnose cases of variant Creutzfeldt-Jakob Disease (vCJD), a rare, fatal brain disease caused by proteins known as prions. These prions are also responsible for the mad cow disease, or bovine spongiform encephalopathy (BSE). This test could in near future be used to identify contaminated blood and prevent transmission of the disease during blood transfusions, the researchers said.

6 Feb 2011

Airborne prions can induce mad cow disease: Research

Airborne prions are also infectious and can induce mad cow disease or Creutzfeldt-Jakob disorder. This is the surprising conclusion of researchers at the University of Zurich, the University Hospital Zurich and the University of Tübingen. They recommend precautionary measures for scientific labs, slaughterhouses and animal feed plants.

14 Jan 2011

Plasminogen may serve as new target to treat prion diseases

Scientists at the University of Kentucky have discovered that plasminogen, a protein used by the body to break up blood clots, speeds up the progress of prion diseases such as mad cow disease.

11 Jan 2011

Omega-3 fatty acid may help protect against traumatic brain injury

Animal experiments suggest that taking the omega-3 fatty acid docosahexanoic acid (DHA) might offer a new way of protecting against traumatic brain injury (TBI), reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

10 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

18F-FDG PET scans help evaluate cognitive dysfunction of pediatric fever-induced epilepsy

Sudden, catastrophic childhood epilepsy is a parent's worst nightmare, especially in the case of fever-induced refractory epileptic encephalopathy in school-age children (FIRES). While not much is known about the condition, new research published in the January issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans can offer an evaluation of cognitive dysfunction of FIRES, its evolution and further prognosis.

4 Jan 2011

Researchers perform cord blood cell transplantation to treat child with ischemic brain injury

In three monthly injections, researchers transplanted neurally-committed, autologous cord blood derived cells tagged with iron oxide nanoparticles into the lateral cerebral ventricle of a 16-month old child with severe global hypoxic ischemic brain injury.

22 Dec 2010

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.

16 Dec 2010

Dobkin's technique delays brain damage in heart attack victims

After a heart attack and the victim stops breathing, a process of irreversible brain damage starts to occur within 3 to 4 minutes. Or does it?

8 Dec 2010

NIAID researchers develop new method to detect prion diseases

A fast test to diagnose fatal brain conditions such as mad cow disease in cattle and Creutzfeldt-Jakob disease in humans could be on the horizon, according to a new study from National Institutes of Health scientists. Researchers at NIH's National Institute of Allergy and Infectious Diseases (NIAID) have developed a highly sensitive and rapid new method to detect and measure infectious agents called prions that cause these diseases.

3 Dec 2010

Scientists find new protein to break-up blood clots in prion diseases

The joy of a juicy hamburger could make a comeback thanks a new discovery by scientists from the University of Kentucky. In a new research report in the December 2010 print issue of The FASEB Journal, scientists found that a protein our body uses to break up blood clots speeds up the progress of prion diseases. This substance, called plasminogen, is a new drug target for prion diseases in both humans and animals.

2 Dec 2010

Dec. 1 news from RSNA 2010

The risk of developing radiation-induced cancer from computed tomography (CT) may be lower than previously thought, according to a Stanford University study. Using more than 10 million Medicare claims from 1998 through 2005, the researchers analyzed the distribution of CT scans, determined the ionizing radiation exposure associated with the exams and estimated the associated cancer risk in a population of older adults.

1 Dec 2010